Zynerba Pharmaceuticals, Inc. (ZYNE)
After hours: 05:50PM EDT
Chart Events
Performance Outlook
| Previous Close | 4.1300 |
| Open | 4.1300 |
| Bid | 4.0000 x 1100 |
| Ask | 4.0700 x 1200 |
| Day's Range | 4.0400 - 4.1300 |
| 52 Week Range | 3.1500 - 9.0000 |
| Volume | 1,883,370 |
| Avg. Volume | 1,720,633 |
| Market Cap | 167.481M |
| Beta (5Y Monthly) | 2.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0820 |
| Earnings Date | Nov 08, 2021 - Nov 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.63 |
Fair Value
Related Research
- Zynerba Pharmaceuticals, Inc.CARA: Lowering target price to $11.00CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat10 days agoArgus Research
- GlobeNewswire
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition
DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American Academy of Pediatrics (AAP) National Conference & Exhibition, which will be held virtually from October 8-11, 2021. A copy of the poster titled, “Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol
- GlobeNewswire
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET. Investors interested in arranging a virtua
- GlobeNewswire
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announces the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-cent
